Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7423615
Reference Type
Journal Article
Title
Basis of Therapeutic Nuclear Medicine
Author(s)
Elgazzar, AH; Al-Bader, A; Abdel-Dayem, HM; ,
Year
2015
Publisher
Springer International Publishing
Location
Cham
Book Title
The Pathophysiologic Basis of Nuclear Medicine
Page Numbers
689-713
DOI
10.1007/978-3-319-06112-2_20
URL
http://link.springer.com/10.1007/978-3-319-06112-2_20
Exit
Abstract
Therapeutic applications of nuclear medicine are expanding (Table 20.1). Until few years ago, the use of radioisotopes in therapy was limited predominantly to treatment of hyperthyroidism, thyroid cancer, and polycythemia rubra vera. Strontium-89 (Sr-89), rhenium-186 (Re-186), samarium-153 (Sm-153), and tin-117m (Sn-117) have been increasingly used more recently in treating bone pain secondary to metastases. Additionally, treatment of certain neuroendocrine tumors with I-131 MIBG and labeled octreotide and pentreotide, the use of radiolabeled monoclonal antibodies for lymphomas, radionuclide treatment of primary and secondary liver lesions, and radionuclide synovectomy have revolutionized the field of therapeutic nuclear medicine.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity